NEW YORK (GenomeWeb News) – Horizon Discovery today announced a research collaboration and licensing deal with AstraZeneca to interrogate oncology-relevant genotypes in order to identify and validate new drug targets.

Horizon will query a defined set of genotypes for synthetic lethality and carry out in vitro screening using the company's siRNA platform, as part of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.